Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.54 |
| ▸ | MMP9 | P14780 | 17/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 5/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 4/20 | 0.46 |
| ▸ | MMP14 | P50281 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377157 | 0.95 | MMP2 (0.52) | MMP2MMP9ADAMTS5MMP8MMP13 | |
| SCHEMBL1380421 | 0.94 | MMP2 (0.54) | MMP2MMP9ADAMTS5MMP8MMP13 | |
| SCHEMBL1380422 | 0.94 | MMP2 (0.54) | MMP2MMP9ADAMTS5MMP8MMP13 | |
| SCHEMBL1378296 | 0.92 | MMP2 (0.54) | MMP2MMP9ADAMTS5MMP8MMP13 | |
| SCHEMBL1378295 | 0.92 | MMP2 (0.54) | MMP2MMP9ADAMTS5MMP8MMP13 | |
| SCHEMBL1380247 | 0.90 | MMP9 (0.54) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| Hydroxyamine SCHEMBL7536560 | 0.88 | MMP9 (0.55) | MMP2MMP9MMP8MMP13ADAMTS4 | |
| SCHEMBL1379841 | 0.86 | BMP1 (0.49) | MMP2MMP9ADAMTS5MMP14 | |
| SCHEMBL1378261 | 0.85 | BMP1 (0.48) | MMP2MMP9ADAMTS5MMP14 | |
| SCHEMBL1378262 | 0.85 | BMP1 (0.48) | MMP2MMP9ADAMTS5MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4750272-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | claimed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | claimed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |